James C. Edgemond's Insider Trades & SAST Disclosures
James C. Edgemond's most recent trade in United Therapeutics Corp was a trade of 3,400 Stock Options done . Disclosure was reported to the exchange on Nov. 4, 2024.
Add Superstar Alert
Note
This is a custom search result for pattern James C. Edgemond.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2024 | 3,400 | 112,350 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 374.02 per share. | 04 Nov 2024 | 3,400 | 7,512 (0%) | 0% | 374.0 | 1,271,668 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 04 Nov 2024 | 3,400 | 10,912 (0%) | 0% | 117.8 | 400,384 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 120.26 per share. | 04 Nov 2024 | 3,267 | 10,779 (0%) | 0% | 120.3 | 392,889 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2024 | 3,267 | 817 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 374.02 per share. | 04 Nov 2024 | 3,267 | 7,512 (0%) | 0% | 374.0 | 1,221,923 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2024 | 850 | 111,500 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 04 Nov 2024 | 850 | 8,633 (0%) | 0% | 117.8 | 100,096 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2024 | 817 | 0 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 120.26 per share. | 04 Nov 2024 | 817 | 8,329 (0%) | 0% | 120.3 | 98,252 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 374.02 per share. | 04 Nov 2024 | 565 | 8,068 (0%) | 0% | 374.0 | 211,321 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 374.02 per share. | 04 Nov 2024 | 546 | 7,783 (0%) | 0% | 374.0 | 204,215 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2024 | 3,400 | 116,600 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 28 Oct 2024 | 3,400 | 10,378 (0%) | 0% | 117.8 | 400,384 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 350.00 per share. | 28 Oct 2024 | 3,400 | 6,978 (0%) | 0% | 350 | 1,190,000 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 120.26 per share. | 28 Oct 2024 | 3,267 | 10,245 (0%) | 0% | 120.3 | 392,889 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 350.00 per share. | 28 Oct 2024 | 3,267 | 6,978 (0%) | 0% | 350 | 1,143,450 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2024 | 3,267 | 4,901 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2024 | 850 | 115,750 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 28 Oct 2024 | 850 | 8,088 (0%) | 0% | 117.8 | 100,096 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2024 | 817 | 4,084 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 120.26 per share. | 28 Oct 2024 | 817 | 7,795 (0%) | 0% | 120.3 | 98,252 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 350.00 per share. | 28 Oct 2024 | 576 | 7,512 (0%) | 0% | 350 | 201,600 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 350.00 per share. | 28 Oct 2024 | 557 | 7,238 (0%) | 0% | 350 | 194,950 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 21 Oct 2024 | 3,400 | 9,826 (0%) | 0% | 117.8 | 400,384 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 366.99 per share. | 21 Oct 2024 | 3,400 | 6,426 (0%) | 0% | 367.0 | 1,247,766 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2024 | 3,400 | 120,850 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 366.99 per share. | 21 Oct 2024 | 3,267 | 6,426 (0%) | 0% | 367.0 | 1,198,956 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 120.26 per share. | 21 Oct 2024 | 3,267 | 9,693 (0%) | 0% | 120.3 | 392,889 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2024 | 3,267 | 8,985 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2024 | 850 | 120,000 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 21 Oct 2024 | 850 | 7,545 (0%) | 0% | 117.8 | 100,096 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2024 | 817 | 8,168 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 120.26 per share. | 21 Oct 2024 | 817 | 7,243 (0%) | 0% | 120.3 | 98,252 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 366.99 per share. | 21 Oct 2024 | 567 | 6,978 (0%) | 0% | 367.0 | 208,083 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 366.99 per share. | 21 Oct 2024 | 548 | 6,695 (0%) | 0% | 367.0 | 201,111 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 177.76 per share. | 14 Oct 2024 | 3,400 | 9,284 (0%) | 0% | 177.8 | 604,384 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 355.88 per share. | 14 Oct 2024 | 3,400 | 5,884 (0%) | 0% | 355.9 | 1,209,992 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 3,400 | 125,100 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 120.26 per share. | 14 Oct 2024 | 3,267 | 9,151 (0%) | 0% | 120.3 | 392,889 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 355.88 per share. | 14 Oct 2024 | 3,267 | 5,884 (0%) | 0% | 355.9 | 1,162,660 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 3,267 | 13,069 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 14 Oct 2024 | 850 | 6,998 (0%) | 0% | 117.8 | 100,096 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 850 | 124,250 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 120.26 per share. | 14 Oct 2024 | 817 | 6,701 (0%) | 0% | 120.3 | 98,252 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 817 | 12,252 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 355.88 per share. | 14 Oct 2024 | 572 | 6,426 (0%) | 0% | 355.9 | 203,563 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 355.88 per share. | 14 Oct 2024 | 553 | 6,148 (0%) | 0% | 355.9 | 196,802 | Common Stock |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2024 | 3,400 | 129,350 | - | - | Stock Options | |
|
United Therapeutics Corp
|
James C. Edgemond | CFO AND TREASURER | Sale of securities on an exchange or to another person at price $ 355.54 per share. | 07 Oct 2024 | 3,400 | 5,344 (0%) | 0% | 355.5 | 1,208,836 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges